Table 3 Analyses of Risk Factors for depression among Patients with glaucoma

 30–50

Reference

Reference

 50–60

1.56(1.23–1.99)

< 0.001

1.39(1.09–1.77)

< 0.001

 60–70

1.31(1.03–1.68)

< 0.05

1.27(1.03–1.58)

< 0.05

  ≥ 70

1.56(1.22–1.99)

< 0.001

1.35(1.06–1.78)

< 0.05

Gender (Male vs. Female)

0.64(0.54–0.76)

< 0.0001

0.71(0.60–0.84)

< 0.0001

  < 3

Reference

Reference

  ≥ 3

1.18(0.94–1.49)

0.15

1.16(0.92–1.47)

0.23

  < 40,000 NTD

Reference

Reference

  ≥ 40,000 NTD

0.44(0.32–0.61)

< 0.0001

0.53(0.38–0.75)

< 0.001

 Urban

Reference

Reference

 Rural

1.07(0.88–1.30)

0.49

0.97(0.80–1.18)

0.77

 No

Reference

Reference

 Yes

1.36(1.06–1.73)

< 0.05

1.34(1.03–1.73)

< 0.05

 No

Reference

Reference

 Yes

1.62(1.08–2.87)

< 0.05

1.51(1.02–2.57)

< 0.05

  < 3

Reference

Reference

  ≥ 3

0.88(0.70–1.11)

0.28

0.83(0.60–1.16)

0.28

 Sympathomimetics (Yes vs. No)

0.91(0.76–1.08)

0.28

0.68(0.36–1.28)

0.23

 Pilocarpine (Yes vs. No)

1.52(0.92–2.30)

0.11

1.57(0.93–2.10)

0.10

 Carbonic anhydrase inhibitors (Yes vs. No)

0.82(0.67–1.01)

0.07

0.89(0.69–1.14)

0.35

 β-blocker (Yes vs. No)

1.00(0.85–1.19)

0.97

1.07(0.88–1.29)

0.51

 Prostaglandin analogs (Yes vs. No)

0.94(0.79–1.14)

0.54

1.40(0.74–2.68)

0.31